TOI
The Oncology Institute, Inc. NASDAQ$4.08
Mkt Cap $403.3M
52w Low $2.02
72.1% of range
52w High $4.88
50d MA $3.15
200d MA $3.44
P/E (TTM)
-7.5x
EV/EBITDA
-115.3x
P/B
—
Debt/Equity
-6.6x
ROE
385.5%
P/FCF
-118.4x
RSI (14)
—
ATR (14)
—
Beta
0.20
50d MA
$3.15
200d MA
$3.44
Avg Volume
1.8M
About
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palli…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.08 | -0.06 | +25.0% | 2.62 | +19.8% | +8.4% | +30.2% | +37.0% | +37.4% | +35.1% | +26.0% | — |
| Nov 13, 2025 | AMC | -0.12 | -0.14 | -16.7% | 3.08 | +2.9% | +28.9% | +22.4% | +22.4% | +6.2% | +5.2% | +22.4% | — |
| Aug 13, 2025 | AMC | -0.14 | -0.14 | +0.0% | 4.10 | -2.7% | -10.5% | -8.3% | -1.5% | -6.8% | -8.8% | -25.6% | — |
| May 14, 2025 | AMC | — | -0.17 | — | 2.37 | +19.4% | +28.3% | +26.2% | +29.1% | +17.3% | +13.1% | +4.2% | — |
| Mar 24, 2025 | AMC | -0.08 | -0.14 | -75.0% | 1.24 | -1.6% | +1.6% | -2.4% | -10.5% | -8.1% | -8.1% | +132.3% | — |
| Nov 13, 2024 | AMC | -0.07 | -0.18 | -157.1% | 0.26 | +0.0% | -10.8% | -31.8% | -36.3% | -31.8% | -49.9% | -15.5% | — |
| Aug 13, 2024 | AMC | -0.10 | -0.17 | -70.0% | 0.55 | -5.9% | -18.2% | -34.9% | -37.3% | -40.5% | -27.3% | -45.5% | — |
| May 14, 2024 | AMC | -0.12 | -0.22 | -83.3% | 0.90 | -1.6% | -24.0% | -25.2% | -29.0% | -32.2% | -33.8% | -48.4% | — |
| Mar 27, 2024 | AMC | -0.11 | -0.21 | -90.9% | 1.84 | -3.3% | -14.1% | -15.2% | -16.3% | -19.0% | -18.5% | -37.5% | — |
| Nov 8, 2023 | AMC | -0.13 | -0.19 | -46.2% | 1.84 | +5.4% | +27.7% | +34.2% | +38.6% | +31.0% | +20.7% | -31.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $2.62 | $3.14 | +19.8% | +8.4% | +30.2% | +37.0% | +37.4% | +35.1% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $2.62 | $3.14 | +19.8% | +8.4% | +30.2% | +37.0% | +37.4% | +35.1% |
| Mar 9 | BTIG | Maintains | Buy → Buy | — | $2.78 | $2.70 | -2.9% | -1.8% | -6.1% | -0.7% | -5.8% | +2.2% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $2.78 | $2.70 | -2.9% | -1.8% | -6.1% | -0.7% | -5.8% | +2.2% |
| Oct 21 | BTIG | Maintains | Buy → Buy | — | $4.24 | $4.19 | -1.2% | +0.5% | +3.5% | +8.7% | +12.0% | +8.7% |
| Jun 16 | Guggenheim | Maintains | Buy → Buy | — | $0.61 | $0.63 | +4.1% | +2.8% | -1.0% | -0.5% | -10.9% | -7.6% |
| Mar 20 | Guggenheim | Maintains | Neutral → Neutral | — | $0.48 | $0.50 | +3.5% | +6.0% | +39.3% | +70.5% | +67.6% | +49.7% |
| Nov 11 | Guggenheim | Maintains | Buy → Buy | — | $2.94 | $2.91 | -1.0% | -26.2% | -28.9% | -30.6% | -32.7% | -36.4% |
| Aug 15 | Jefferies | Maintains | Buy → Buy | — | $6.51 | $6.08 | -6.6% | -4.9% | +3.8% | +4.8% | +7.5% | +2.9% |
Recent Filings
8-K
Unknown — 8-K Filing
TOI's full-year 2025 results and 2026 guidance will reveal whether its value-based oncology model is generating sustainable growth and profitability, directly impacting revenue trajectory and investor confidence.
Mar 12
8-K · 5.02
!!! Very High
The Oncology Institute, Inc. -- 8-K 5.02: Executive Change
The Oncology Institute appointed Ms. Tzoumakas as a director effective February 23, 2026, expanding its board composition.
Feb 23
Data updated apr 27, 2026 5:15am
· Source: massive.com